Trial of NovoSeven® in Haemophilia - Joint Bleeds

Novo Nordisk A/S42 enrolled

Overview

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Congenital Bleeding Disorder Haemophilia A With Inhibitors Haemophilia B With Inhibitors

Interventions

eptacog alfa (activated)DRUG

Feiba VHDRUG

Eligibility

Sex: MALEMax age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively

Locations (20)

Novo Nordisk Investigational Site

Little Rock, Arkansas, United States

Outcomes

Primary Outcomes

Comparison with FEIBA on review of pain, joint mobility and circumference

Time frame: after 1, 3, 6, and 9 hours of treatment, respectively

Secondary Outcomes

Safety variables

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.